A Phase II Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 (c[alpha]Stx1) and 2 (c[alpha]Stx2) Administered Concomitantly to Children With Shiga Toxin-Producing Bacterial (STPB) Infection and Bloody Diarrhea (SHIGATEC Trial).

Trial Profile

A Phase II Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 (c[alpha]Stx1) and 2 (c[alpha]Stx2) Administered Concomitantly to Children With Shiga Toxin-Producing Bacterial (STPB) Infection and Bloody Diarrhea (SHIGATEC Trial).

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2015

At a glance

  • Drugs Anti-Shiga toxin monoclonal antibodies (Primary)
  • Indications Shiga-toxigenic Escherichia coli infections
  • Focus Adverse reactions
  • Acronyms SHIGATEC
  • Sponsors BELLUS Health
  • Most Recent Events

    • 09 Sep 2015 Results will be presented at the International Symposium on Shiga toxin (verocytotoxin) Producing Escherichia Coli (VTEC) 2015 conference, according to a BELLUS Health media release.
    • 29 Apr 2013 Status changed from active, no longer recruiting to completed.
    • 09 May 2012 Top-line results have been presented at the 8th International Symposium on Shiga Toxin (Verocytotoxin)-Producing Escherichia coli Infections (VTEC 2012), as reported by Thallion Pharmaceuticals and LFB Biotechnologies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top